TokenPost·
Viridian Therapeutics Posts $24.7 Million in Lumvoa Net Product Revenue for Q3 2026
Total revenue was $25.752 million, and GAAP net loss per share was $0.81 on both basic and diluted bases.
More news
- TokenPostAssured Guaranty Sets Dec. 2 Payment for $0.38 Quarterly Dividend
- TokenPostRiot Completes Digital Asset Custody Transfer From NYDIG to BitGo
- TokenPostBernstein Raises TSMC Price Target to $600 From $554, a $46 Increase
- TokenPostTexas Elects James Talarico, a Backer of a Proposed State Bitcoin Reserve
- TokenPostXPEL Q3 Revenue Climbs 9.9% to $137.8 Million as Net Income Rises 26.3%
- Crypto BriefingArkham adds frozen asset view to its portfolio module